Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07053072 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

PD-1 mRNA LNP Vaccine for Advanced Primary Hepatocellular Carcinoma.

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 months later Sep 30, 2026 → Dec 30, 2026
See other at-risk trials from West China Hospital

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Sep 30, 2026 to Dec 30, 2026
    • Eligibility criteria expanded, about 24 words
    • Secondary endpoints: details revised at 1 of 7 entries
    • Publications: details revised at 13 of 13 entries
  2. Re-verified, no change to tracked fieldsv4
  3. Phase: Phase 1/2 to Phase 1v3 Show 4 more changesShow less
    • Primary endpoint revised
    • Interventions: High dose PD-1 mRNA LNP vaccines (Drug), Low Dose PD-1 mRNA LNP Vaccine (Drug), Medium dose PD-1 mRNA LNP vaccines (Drug) to High dose PD-1 mRNA LNP vaccines (Drug), Low Dose PD-1 mRNA LNP Vaccine (Drug)
    • Secondary endpoints: details revised at 7 of 7 entries
    • Study arms: 3 to 2
  4. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Primary completion date: Jul 30, 2025 to Sep 30, 2026
    • Start date changed from estimate of Jul 15, 2025 to Oct 23, 2025
    • Study sites: 1 to 2
    • Publications: details revised at 13 of 13 entries
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
West China Hospital
264 trials monitored
See 13 trials at risk
Liver Cancer
1,598 trials monitored
See 71 trials at risk
Evaluating the Safety and Efficacy of PD-1 mRNA LNP Vaccine Therapy in Patients with Primary Hepatocellular Carcinoma Who Have Failed Advanced Standard Therapy
Trial Details
NCT Number NCT07053072
Lead Sponsor West China Hospital
Conditions
(from sponsor)		 Liver Cancer
Related terms Liver Neoplasms
Enrollment 9 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov